PRESS RELEASE June 20, 2013

EpiCept Issues Notice of Special Meeting of Stockholders on August 6 to Approve Important Aspects of the Proposed Merger with Immune Pharmaceuticals

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News : EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX: EPCT) today issued notice that stockholders of EpiCept are invited to the Special Meeting of Stockholders (the “Special Meeting”) to be held on August 6, 2013 at 11:00 a.m. Eastern Daylight Time at the Company’s offices at 777 Old Saw Mill River […]

Keep Reading

PRESS RELEASE June 3, 2013

EpiCept Announces New Crolibulin Data Presented at ASCO 2013 Support Further Evaluation in Anaplastic Thyroid Cancer

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that new data supporting further evaluation of crolibulin were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO 2013), taking place May 31 to June 4, 2013 at the McCormick Place Convention Center in Chicago. Crolibulin […]

Keep Reading

PRESS RELEASE May 22, 2013

CEO of Immune Pharmaceuticals to Present at BioEquity Europe 2013

HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Daniel Teper, Chief Executive Officer of Immune, will be presenting at the BioEquity Europe 2013 conference at the Varumottagning Sheraton Hotel in Stockholm, Sweden on […]

Keep Reading

PRESS RELEASE May 20, 2013

EpiCept Reports First Quarter 2013 Operating and Financial Results

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the three months ended March 31, 2013, and provided an update on the Company’s planned merger with Immune Pharmaceuticals, Ltd. (Immune). Robert Cook, Interim President and CEO of EpiCept, commented, “With the filing of […]

Keep Reading

PRESS RELEASE February 28, 2013

EpiCept Reports Fourth Quarter and Full Year 2012 Operating and Financial Results

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company’s merger with Immune Pharmaceuticals, Ltd. (Immune). Robert Cook, Interim President and CEO of EpiCept, commented, “While we […]

Keep Reading

PRESS RELEASE February 21, 2013

Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis

HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe […]

Keep Reading

PRESS RELEASE February 12, 2013

EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement

HERZLIYA-PITUACH, Israel & TARRYTOWN, N.Y. –(BUSINESS WIRE)– Regulatory News : Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, and EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that they have executed an amendment to the Merger Agreement and Plan of Reorganization that they signed on November 7, 2012. Under the terms […]

Keep Reading

PRESS RELEASE February 6, 2013

EpiCept Corporation to Present at the 15th BIO CEO & Investor Conference

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Robert W. Cook, Interim President and Chief Executive Officer, will be presenting at the 15th BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 2:30 PM local time at the Waldorf Astoria, Room Park South, in […]

Keep Reading

PRESS RELEASE January 9, 2013

Daniel Teper of Immune Pharmaceuticals to Present at the 6th Annual OneMedForum

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) announced today that Daniel Teper, Chief Executive Officer of Immune Pharmaceuticals presented at the 6th Annual OneMedForum, on Wednesday, January 9, 2013 at 1:40 PM Pacific time at The Sir Francis Drake hotel in San Francisco, California. Mr. Teper presented a […]

Keep Reading

PRESS RELEASE November 14, 2012

EpiCept Reports Third Quarter 2012 Operating and Financial Results

TARRYTOWN, N.Y.–(BUSINESS WIRE)– Regulatory News : EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) (the Company) today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million. These compare with net losses for the […]

Keep Reading